Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Ph-like ALL and new genetic subtypes

Marina Konopleva • 27 Aug 2020
SOHO Italy 2020
Acute Lymphoblastic Leukemia Leukemia Blinatumomab Imatinib Inotuzumab ozogamicin

Marina Konopleva, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses Ph-like acute lymphoblastic leukemia (ALL), a poor responding subset of ALL, that shares similar genetic abnormalities as Ph-positive chronic lymphocytic leukemia, without t[9;22]. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Marina Konopleva

2:41
Advancements in AML: an update from ASH 2023
Marina Konopleva • 8 Dec 2023
1:36
The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva • 8 Dec 2023
1:03
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva • 8 Dec 2023
1:17
Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals